Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 19/20 | 0.74 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31572862 | 0.90 | IGF1R (0.68) | IGF1R | |
| SCHEMBL31573076 | 0.90 | IGF1R (0.63) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL31573035 | 0.90 | IGF1R (0.63) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL31572890 | 0.90 | IGF1R (0.63) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL31330670 | 0.88 | IGF1R (0.59) | IGF1R | |
| SCHEMBL31330308 | 0.88 | IGF1R (0.73) | IGF1R | |
| SCHEMBL31572930 | 0.88 | IGF1R (0.60) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL31572987 | 0.88 | IGF1R (0.68) | IGF1R | |
| SCHEMBL31573031 | 0.87 | IGF1R (0.58) | IGF1RPPARGPPARDPPARA | |
| SCHEMBL31330333 | 0.87 | IGF1R (0.75) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747242-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | Horizon Therapeutics Ireland Dac (IE) | 2026-05-27 | — | — | EP | disclosed |
| US-20250145585-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-08 | — | — | US | disclosed |
| WO-2025019715-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145585-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TSHR, TRHR | IGF1R 1/4885PPARG 248/4885PPARD 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.